Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gilteritinib plus azacitidine versus azacitidine in newly diagnosed FLT3-mutated acute myeloid leukemia in patients ineligible for intensive induction chemotherapy
2015-001790-41Phase 3Active
- Sponsor
- Astellas Pharma
- Start
- Apr 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in acute myeloid leukemia (AML) comparing Gilteritinib plus azacitidine with Azacitidine alone (2 arms). Primary endpoints: Overall Survival and Event-Free Survival. Started Apr 2016; status: active.
02
Drugs
gilteritinibazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2015-001790-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001790-41.